Pharma R&D Today

Ideas and Insight supporting all stages of Drug Discovery & Development

Select category
Search this blog

Robots, Reactions & Automated Labs

Posted on April 18th, 2019 by

Pharma R&D

Elseiver’s Elia Lima-Watson, MD explores the phenomenon of automation int he lab beyond just rote tasks. Fascinating developments in this field and others continue to accelerate the discovery process at a dizzying rate.

(more…)

Machine Learning Is Accelerating the Pace of Drug Development, But Good Data is Key

Posted on April 17th, 2019 by

Pharma R&D

Artificial Intelligence, Machine Learning and Deep Learning are on the tip of everyone’s tongues when it comes to acceleration of the pace of discovery The Pharma R&D market is a perfect exemplification of this phenomenon. Medical advancements enabled by such technologies have proven to significantly accelerate discovery processes, saving valuable time and money required for the development of life changing solutions. That being said, there is the reality that human beings with a passion and talent for feeding such mechanisms still and likely always will provide invaluable inputs. In short, we are not to be replaced by these advancements; rather the changes are indicative of a new era of advancement defined by “partnerships” between humans and machines.

(more…)

Integrating Chemistry Data Sources Provides Big Benefits

Posted on April 17th, 2019 by

Pharma R&D

Unification across platforms is providing multiple benefits to organizations who pull together massive amounts of data across multiple platforms. Technology is evolving to eliminate data redundancy and silos as evidenced by the collaboration between Elsevier and Lundbeck.

(more…)

Working together to get the best out of AI for all

Posted on April 16th, 2019 by

Pharma R&D

Go to any conference these days and the number one buzzword is AI. However, despite all the excitement, AI is still talked about in fairly vague terms – with few people able to pin down exactly what they mean by AI. New research from some of my Elsevier colleagues examined this phenomenon.

(more…)

Beacon Discovery Leverages Partnerships and Elsevier Solutions to Further GCPR R&D Related Research

Posted on April 13th, 2019 by

Pharma R&D

Molecular Dreams series. Backdrop of conceptual atoms.

Beacon Discovery is a selected member of Elsevier’s The Hive, which is a partnership engine supporting innovation and R&D with emerging biotech startups. Here, Dr. Carleton Sage explains how leveraging the Elsevier suite of solutions in conjunction with an impassioned approach to GCPR research, Beacon Discovery has made significant strides in the discovery process to solve unmet medical needs.

(more…)

Collaboration Drives an Exciting Development for In Silico Disease Modeling

Posted on April 9th, 2019 by

Pharma R&D

Partnerships between organizations with complementary goals and capabilities are increasingly proving to pave paths towards revolutionary advancements in life sciences. One such partnership is highlighted between Elsevier and Rochester General Hospital at ConTech 2018 in the field of In Silico Disease Modelling.

(more…)

  1. 1
  2. 2
  3. 3
  4. 63


About this Blog

iStock_000019748868_Full

The Elsevier Pharma R&D blog provides insight and opinion on topics related to pharmaceutical research and development, namely: big data, target identification, new drug discovery, drug safety monitoring, risk mitigation and regulatory compliance. We serve the community of chemists, scientists, drug safety specialists, educators and students interested in pharmaceutical R&D.

Editor’s note: The views and opinions expressed are those of the author and do not necessarily reflect the views of Elsevier,  its affiliates and sponsors or its parent company, Reed Elsevier.